Systemic Lupus Erythematosus Epidemiology

Epidemiology Insights and Trends

• According to DelveInsight’s estimates, the total diagnosed prevalent cases of SLE in the 7MM were approximately 911,600 in 2025.
• In 2026, gender-based diagnosed prevalent SLE cases across the USA are expected to include 9% cases in males and 91% cases in females, reinforcing the disease’s strong female predominance and highlighting the role of hormonal and immune-mediated mechanisms in shaping SLE susceptibility, driving its population-level burden.
• Moderate-to-severe disease accounts for the majority of the SLE patient population, with only a minority presenting with mild disease, a distribution that directly amplifies healthcare resource utilization, per-patient costs, and the urgency for more effective, targeted therapeutic interventions capable of meaningfully altering disease trajectory.
• The SLE is found to be more prevalent in females than in males.

Systemic Lupus Erythematosus (SLE) Epidemiology Forecast in the United States

• 2025 Prevalent Cases of Systemic Lupus Erythematosus (SLE): ~911,600
• Systemic Lupus Erythematosus (SLE) Growth Rate (2026–2036): ~2.2% CAGR

DelveInsight's ‘Systemic Lupus Erythematosus (SLE) – Epidemiology Forecast – 2036’ report delivers an in-depth understanding of the SLE, historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Systemic Lupus Erythematosus (SLE) Understanding and Diagnosis Algorithm

Systemic Lupus Erythematosus (SLE) Overview

SLE is a chronic autoimmune disease that can affect virtually any organ system, with manifestations ranging from mild skin and joint involvement to severe neurological and systemic complications. SLE is the most common form of lupus, accounting for nearly 70% of all cases. The disease has a multifactorial origin, with genetic susceptibility and environmental triggers contributing to immune dysregulation, where the immune system mistakenly attacks the body’s own tissues. While skin and joints are most commonly affected, organ involvement varies widely among patients. SLE typically follows a relapsing–remitting course, with periods of flares alternating with remission or low disease activity.

The diagnosis of SLE is complex due to its heterogeneous clinical presentation and lack of a single definitive diagnostic marker. Diagnosis relies on a comprehensive evaluation of clinical manifestations and serological testing, including antinuclear antibodies (ANA), anti-dsDNA, and anti-Smith antibodies, supported by complement levels and other laboratory findings. Imaging may be used to assess organ involvement, while biopsies particularly renal biopsy in suspected lupus nephritis—provide histopathological confirmation and help guide management decisions.

Further details are provided in the report.

Systemic Lupus Erythematosus (SLE) Epidemiology

Key Findings from Systemic Lupus Erythematosus (SLE) Epidemiological Analysis and Forecast

• According to DelveInsight’s estimates, the total diagnosed prevalent cases of SLE in the 7MM were approximately 911,600 in 2025.
• It has been observed that the prevalence of SLE is higher in adults aged 40-59 years, ~42% as compared to other age groups (0-18 years, 19-39 years and above 60+ years) in the 7MM.
• In 2025, among severity of SLE in the US, moderate SLE was the most prevalent subtype (~261,600 cases), followed by mild SLE cases.
• The total diagnosed prevalent population of SLE across EU4 and the UK has shown a steady upward trend which accounts for 309,400 cases in 2025.
• The SLE is found to be more prevalent in females than in males.

Scope of the Report

• The report covers a segment of an executive summary, a descriptive overview of SLE, explaining its causes, signs and symptoms, and pathogenesis.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.

Report Insights

• SLE Patient Population Forecast

Report Key Strengths

• Epidemiology-based (epi-based) Bottom-up Forecasting
• 11-year Forecast
• Patient Burden Trends (by geography)

FAQs

• What are the disease risks, burdens, and unmet needs of SLE? What will be the growth opportunities across the 7MM concerning the patient population with SLE?
• What is the historical and forecasted SLE patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?

Reasons to Buy

• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand key opinion leaders’ perspectives around the diagnostic challenges to overcome barriers in the future.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.